Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BEIGENE NZ UNLIMITED,Tislelizumab (with platinum-based chemotherapy),"Advanced non-small cell lung cancer, 1st line combination therapy, irrespective of PDL-1 status",Tislelizumab (with platinum-based chemotherapy) (Tevimbra),,Hospital,
